Abstract
Positron emission tomography combined with computed tomography (PET/CT) with 18F-fluoro-deoxyglucose (18F-FDG) plays an important role in the management of cancer patients and is mainly used for primary staging, evaluation of treatment response and detection of disease recurrence. Due to non-specific nature of 18F-FDG uptake, a radiologist must be familiar with both physiological and atypical distribution of radiopharmaceuticals. Inappropriate patient preparation for the study and/or taking certain drugs can lead to abnormal 18F-FDG distribution. Our clinical case demonstrates an atypical uptake of 18F-FDG in white adipose tissue in a child treated with glucocorticoids for a long time.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
